News – Page 1026 – Endpoints News

Merck's Keytruda builds a commanding lead in frontline lung cancer with data from two more landmark trials

7 years ago

Spurring move to personalized therapies, Loxo elbows its way back into the ASCO spotlight with 2nd tissue-agnostic ...

7 years ago

Roche boasts of stalling lung cancer with Tecentriq/chemo combo -- but rival Merck stays out front

7 years ago

Bluebird, Celgene add a promising chapter to their success story with BCMA-targeting CAR-T — and turn it around ...

7 years ago

FDA stalls yet another Herceptin copycat, issuing response letter to Amgen/Allergan

7 years ago

FDA quashes blockbuster dreams at Eli Lilly and Incyte, offering a severely limited approval for Olumiant

7 years ago

Biogen snatches ex-Pfizer exec as new EVP, corporate development; Ionis/Akcea get thumbs up from EMA committee on ...

7 years ago

The FDA and the EMA go their separate ways on DMD: CHMP slaps down Sarepta but offers rival PTC an expanded market

7 years ago

Roche dumps its late-stage SMA drug after gambling up to $545M-plus on the program

7 years ago

Neoantigen pioneer Neon Therapeutics casts off in search of $115M IPO to fuel the race to a personalized cancer ...

7 years ago

Diminishing the FDA’s power was my intent: Right-to-try author scolds Scott Gottlieb as agency implements new law

7 years ago

Bayer scrutinizes R&D group's productivity as staffers fear layoffs in wake of a revamp

7 years ago

Celgene CEO Mark Alles poaches a top J&J exec for his senior crew during a C-suite makeover

7 years ago

J&J racks up a fresh set of positive pivotal data for depression drug esketamine — but questions linger on safety

7 years ago

Dova picked up its newly approved drug castoff for a song — but payers will be singing the blues about the price

7 years ago

Ironwood dodges a Denner board seat, but the activist investor still has words of advice

7 years ago

Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara

7 years ago

ScPharma's stock droops on 'deficiencies' as FDA tosses back heart failure drug application

7 years ago

Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights

7 years ago

Novartis loses a head honcho, with US oncology head Bill Hinshaw exiting for new gig at Axcella

7 years ago

Madrigal shares soar on promising PhII NASH data, stoking hopes for a new contender

7 years ago

Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib — boosting late-stage focus

7 years ago

Following ASCO preview flop, Syndax bets on new combo deal with Nektar

7 years ago

FDA slaps a clinical hold on sickle cell IND filed for a new gene therapy from Vertex and CRISPR Therapeutics

7 years ago

First page Previous page 1023 1024 102510261027 1028 1029 Next page Last page